Computational investigation of the Anti-HIV activity of Chinese medicinal formula Three-Huang Powder

Interdisciplinary Sciences – Computational Life Sciences

Volumn 2, Issue 2, 2010, Pages 151-156

  Hu, Jack Z ^a   Bai, Li ^b   Chen, Da Gang ^c   Xu, Qi Tai ^d   Southerland, William M ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b Taney Academy of Sciences   (United States)

^c Amina International Inc   (United States)

^d HENAN UNIVERSITY   (China)

Author keywords

anti AIDS drug; baicalein; docking; HIV 1 integrase; ligand binding interface; molecular modeling

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; SCUTELLARIA BAICALENSIS;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BAICALEIN; FLAVANONE DERIVATIVE; LIGAND; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BIOLOGY; CHEMICAL STRUCTURE; CHINESE MEDICINE; COMPUTER PROGRAM; CONFORMATION; DRUG DESIGN; ENZYME ACTIVE SITE; HUMAN; METABOLISM; METHODOLOGY; POWDER; PROTEIN BINDING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; CATALYTIC DOMAIN; COMPUTATIONAL BIOLOGY; DNA, VIRAL; DRUG DESIGN; FLAVANONES; HUMANS; LIGANDS; MEDICINE, CHINESE TRADITIONAL; MODELS, MOLECULAR; MOLECULAR CONFORMATION; POWDERS; PROTEIN BINDING; SOFTWARE;

EID: 77956802186     PISSN: 19132751     EISSN: 18671462     Source Type: Journal    
DOI: 10.1007/s12539-010-0074-1     Document Type: Article

References (33)

1. Ahn, H. C., Lee, S. Y., Kim, J. W., Son, W. S., Shin, C. G., Lee, B. J. 2001. Binding aspects of baicalein to HIV-1 integrase. Mol Cells 12, 127-130.
2. Bhattacharya, S., Osman, H. 2009. Novel targets for anti-retroviral therapy. J Infect 59, 377-386.
3. Cheng, C. W., Bian, Z. X., Wu, T. X. 2009. Systematic review of Chinese herbal medicine for functional constipation. World J Gastroenterol 15, 4886-4895.
4. Eron, J. J. J. 2009. Antiretroviral therapy: new drugs, formulations, ideas, and strategies. Top HIV Med 17, 146-150.
5. Ewing, T. J., Makino, S., Skillman, A. G., Kuntz, I. D. 2001. DOCK 4. 0: search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des 15, 411-428.
6. Farnet, C. M., Wang, B., Lipford, J. R., Bushman, F. D. 1996. Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules. Proc Natl Acad Sci USA 93, 9742-9747.
7. Garrido, C., Geretti, A. M., Zahonero, N., Booth, C., Strang, A., Soriano, V., De Mendoza, C. 2010. Integrase variability and susceptibility to HIV integrase inhibitors: Impact of subtypes, antiretroviral experience and duration of HIV infection. J Antimicrob Chemother 65, 320-326.
8. Goldgur, Y., Craigie, R., Cohen, G. H., Fujiwara, T., Yoshinaga, T., Fujishita, T., Sugimoto, H., Endo, T., Murai, H., Davies, D. R. 1999. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design. Proc Natl Acad Sci USA 96, 13040-13043.
9. Gupta, P., Roy, N., Garg, P. 2009. Docking-based 3DQSAR study of HIV-1 integrase inhibitors. Eur J Med Chem 44, 4276-4287.
10. Hu, Z., Southerland, W. 2007. WinDock: Structure-based drug discovery on Windows-based PCs. J Comp Chem 28, 2347-2351.
11. Jenkins, T. M., Esposito, D., Engelman, A., Craigie, R. 1997. Critical contacts between HIV-1 integrase and viral DNA identified by structure-based analysis and photo-crosslinking. EMBO J 16, 6849-6859.
12. Kallings, L. O. 2008. The first postmodern pandemic: 25 years of HIV/AIDS. J Intern Med 263, 218-243.
13. Kiefer, D., Pitluk, J., Klunk, K. 2009. An overview of CAM: components and clinical uses. Nutr Clin Pract 24, 549-559.
14. Lang, P. T., Brozell, S. R., Mukherjee, S., Pettersen, E. F., Meng, E. C., Thomas, V., Rizzo, R. C., Case, D. A., James, T. L., Kuntz, I. D. 2009. DOCK 6: Combining techniques to model RNA-small molecule complexes. RNA 15, 1219-1230.
15. Lawn, S. D. 2004. AIDS in Africa: the impact of coinfections on the pathogenesis of HIV-1 infection. J Infect 48, 1-12.
16. Li, B. Q., Fu, T., Dongyan, Y., Mikovits, J. A., Ruscetti, F. W., Wang, J. M. 2000. Flavonoid baicalin inhibits HIV-1 infection at the level of viral entry. Biochem Biophys Res Commun 276, 534-538.
17. Lubkowski, J., Yang, F., Alexandratos, J., Wlodawer, A., Zhao, H., Burke, T. R. J., Neamati, N., Pommier, Y., Merkel, G., Skalka, A. M. 1998. Structure of the catalytic domain of avian sarcoma virus integrase with a bound HIV-1 integrase-targeted inhibitor. Proc Natl Acad Sci USA 95, 4831-4836.
18. Marchand, C., Maddali, K., Métifiot, M., Pommier, Y. 2009. HIV-1 IN inhibitors: 2010 update and perspectives. Curr Top Med Chem 9, 1016-1037.
19. Matsushita, S. 2000. Current status and future issues in the treatment of HIV-1 infection. Int J Hematol 72, 20-27.
20. McColl, D. J., Chen, X. 2010. Strand transfer inhibitors of HIV-1 integrase: Bringing IN a new era of antiretroviral therapy. Antiviral Res 85, 101-118.
21. Morgan, D., Mahe, C., Mayanja, B., Okongo, J. M., Lubega, R., Whitworth, J. A. 2002. HIV-1 infection in rural Africa: Is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS 16, 597-603.
22. Moszynski, P. 2009. New HIV drug patent pool "offers hope to millions". BMJ 339, b5557.
23. Moustakas, D. T., Lang, P. T., Pegg, S., Pettersen, E., Kuntz, I. D., Brooijmans, N., Rizzo, R. C. 2006. Development and validation of a modular, extensible docking program: DOCK 5. J Comput Aided Mol Des 20, 601-619.
24. Nakanjako, D., Colebunders, R., Coutinho, A. G., Kamya, M. R. 2009. Strategies to optimize HIV treatment outcomes in resource-limited settings. AIDS Rev 11, 179-189.
25. Robinson, W. E. J., Cordeiro, M., Abdel-Malek, S., Jia, Q., Chow, S. A., Reinecke, M. G., Mitchell, W. M. 1996. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: Inhibition of the core catalytic domain of human immunodeficiency virus integrase. Mol Pharmacol 50, 846-855.
26. Schafer, J. J., Squires, K. E. 2010. Integrase inhibitors: A novel class of antiretroviral agents. Ann Pharmacother 44, 145-156.
27. Schneider, M. F., Gange, S. J., Williams, C. M., Anastos, K., Greenblatt, R. M., Kingsley, L., Detels, R., Muñoz, A. 2005. Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS 19, 2009-2018.
28. Tanaka, R., Tsujii, H., Yamada, T., Kajimoto, T., Amano, F., Hasegawa, J., Hamashima, Y., Node, M., Katoh, K., Takebe, Y. 2009. Novel 3alphamethoxyserrat-14-en-21beta-ol (PJ-1) and 3betamethoxyserrat-14-en-21beta-ol (PJ-2)-curcumin, kojic acid, quercetin, and baicalein conjugates as HIV agents. Bioorg Med Chem 17, 5238-5246.
29. Thomsen, R., Christensen, M. H. 2006. MolDock: A new technique for high-accuracy molecular docking. J Med Chem 49, 3315-3321.
30. UNAIDS, WHO (December 2007). "2007 AIDS epidemic update" (PDF). http://data. unaids. org/pub/EPISlides/2007/2007_epiupdate_en. pdf. Retrieved on 12 February 2009.
31. Wang, J. F., Wei, D. Q., Chou, K. C. 2008. Drug candidates from traditional Chinese medicines. Curr Top Med Chem 8, 1656-1665.
32. Weiss, R. A. 1993. How does HIV cause AIDS? Science 260, 1273-1279.
33. Wu, J. A., Attele, A. S., Zhang, L., Yuan, C. S. 2001. Anti-HIV activity of medicinal herbs: usage and potential development. Am J Chin Med 29, 69-81.